UK consults on OTC switch for Bayer's Nasonex

24 November 2016 - Deborah Wilkes

Archived

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is consulting on a proposal to switch Bayer's Nasonex (mometasone furoate) nasal spray from prescription-to-OTC status.

Click tags below for more information on topics:

MHRA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: